.Attributes Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA study, after a typical follow-up of 11 months, patients along with metastatic stomach lumps who got biomarker-matched therapies based on flowing cyst DNA profiling showed a more significant professional perk than those obtaining unequaled treatment.